Modeling and Targeting MYC Genes in Childhood Brain Tumors
Sonja Hutter1, Sara Bolin2, Holger Weishaupt3
1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden. sonja.hutter@igp.uu.se.
Abstract:
Brain tumors are the second most common group of childhood cancers, accounting for about 20%-25% of all pediatric tumors. Deregulated expression of the MYC family of transcription factors, particularly c-MYC and MYCN genes, has been found in many of these neoplasms, and their expression levels are often correlated with poor prognosis. Elevated c-MYC/MYCN initiates and drives tumorigenesis in many in vivo model systems of pediatric brain tumors. Therefore, inhibition of their oncogenic function is an attractive therapeutic target. In this review, we explore the roles of MYC oncoproteins and their molecular targets during the formation, maintenance, and recurrence of childhood brain tumors. We also briefly summarize recent progress in the development of therapeutic approaches for pharmacological inhibition of MYC activity in these tumors.
Insights
MYC oncoproteins drive pediatric brain tumors. Inhibiting their function is a promising therapeutic strategy for these challenging childhood cancers, offering hope for improved outcomes.
Area of Science:
- Pediatric oncology
- Molecular biology
- Cancer genetics
Background:
- Brain tumors represent a significant portion of childhood cancers, with MYC family genes (c-MYC, MYCN) frequently overexpressed.
- Elevated MYC expression is linked to poor prognosis in pediatric brain tumors.
- MYC oncoproteins play a critical role in initiating and sustaining tumor growth.
Purpose of the Study:
- To review the function of MYC oncoproteins and their targets in pediatric brain tumor development, maintenance, and recurrence.
- To summarize current therapeutic strategies targeting MYC activity in these tumors.
Main Methods:
- Literature review of studies on MYC function in pediatric brain tumors.
- Analysis of molecular targets and pathways regulated by MYC.
- Summary of preclinical and clinical developments in MYC-targeted therapies.
Main Results:
- MYC oncoproteins are key drivers of tumorigenesis in various pediatric brain tumor models.
- Understanding MYC's role in tumor formation, maintenance, and recurrence is crucial.
- Emerging therapeutic approaches aim to pharmacologically inhibit MYC activity.
Conclusions:
- Targeting MYC oncoproteins presents a viable therapeutic avenue for pediatric brain tumors.
- Further research into MYC inhibition strategies is warranted for clinical application.
- Pharmacological inhibition of MYC offers potential for improved treatment outcomes in children with brain tumors.
More Related Videos
07:44Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
